A number of research firms have changed their ratings and price targets for bluebird bio (NASDAQ: BLUE):

  • 10/16/2017 – bluebird bio was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $102.00 price target on the stock.
  • 10/11/2017 – bluebird bio had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $126.00 price target on the stock.
  • 10/9/2017 – bluebird bio had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $170.00 price target on the stock, up previously from $100.00.
  • 10/6/2017 – bluebird bio had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $186.00 price target on the stock.
  • 10/6/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $145.00 price target on the stock, up previously from $120.00.
  • 10/2/2017 – bluebird bio was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $105.00 price target on the stock. They wrote, “excitement.” But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm’s Matthew Harrison downgraded Bluebird’s stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to “increase investor confidence” in its sickle cell gene therapy.”Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially,” the analyst explained. “We do not believe the evidence supports current investor optimism that this can be solved by ASH.”
  • 9/30/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $120.00 price target on the stock.
  • 9/28/2017 – bluebird bio had its “sell” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $39.00 price target on the stock. They wrote, “bluebird bio announced that the first multiple myeloma patient was dosed with its next-generation CAR-T product candidate bb21217.””
  • 9/6/2017 – bluebird bio is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $151.00 price target on the stock.
  • 9/5/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $158.00 price target on the stock, up previously from $134.00.
  • 9/1/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $135.00 price target on the stock, up previously from $121.00.
  • 8/31/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Cowen and Company.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 1.19% during trading on Monday, reaching $144.25. The company’s stock had a trading volume of 255,895 shares. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $145.70. The company’s market cap is $6.58 billion. The stock’s 50 day moving average price is $131.07 and its 200 day moving average price is $104.05.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the prior year, the company earned ($1.59) EPS. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. Equities research analysts predict that bluebird bio, Inc. will post ($6.80) EPS for the current year.

In other news, insider Philip D. Gregory sold 750 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $99.00, for a total transaction of $74,250.00. Following the sale, the insider now owns 31,234 shares in the company, valued at approximately $3,092,166. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $120.00, for a total value of $60,000.00. Following the sale, the director now owns 3,300 shares in the company, valued at approximately $396,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,602 shares of company stock worth $17,608,391. Company insiders own 3.90% of the company’s stock.

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.